Kordiamin 250 mg/ml 10 pcs ampoules solution for injection 1 ml

Collapse, asphyxia (including in newborns), shock during surgical operations and in the postoperative period, respiratory and circulatory depression in infectious diseases.

The single and daily doses, as well as the frequency of administration, are determined individually by the physician based on the indications and the patient's age.
The medication is administered subcutaneously, intramuscularly, and intravenously. Adults and children over 14 years are prescribed 1-2 ml 1-3 times a day.
For intravenous administration, the single dose of the medication is diluted in 10 ml of 0.9% sodium chloride solution; it is administered over 1-3 minutes.
Maximum doses for adults for subcutaneous administration: single - 2 ml, daily - 6 ml.
For children, subcutaneous doses are prescribed based on age as follows:
Up to 1 year - 0.1 ml;
1-4 years - 0.15-0.25 ml;
5-6 years - 0.3 ml;
7-9 years - 0.5 ml;
10-14 years - 0.75 ml.
Administered 1-3 times a day.

Active ingredient: niketamide (diethylamide of nicotinic acid) – 250 mg;
Excipients: water for injection up to 1.0 ml.

A clear colorless or slightly yellowish liquid with a characteristic odor.

Hypersensitivity to the components of the drug, epilepsy, history of seizures and predisposition to seizures, hyperthermia in children, pregnancy, breastfeeding period.

Immune system side effects: hypersensitivity reactions, including urticaria, angioedema, generalized papular rashes.
Nervous system side effects: restlessness, increased irritability, anxiety.
Cardiovascular side effects: arrhythmia, arterial hypertension, tachycardia.
Gastrointestinal side effects: nausea, vomiting.
Skin and subcutaneous tissue side effects: redness, facial puffiness, skin peeling, pruritus.
Skeletal muscle and connective tissue side effects: muscle twitching (starting with the circular muscles of the mouth), tremor, muscle rigidity.
General disorders and administration site reactions: hyperthermia, increased sweating, infiltration, tenderness, hyperemia, burning sensation of the skin at the injection site.

Symptoms: exacerbation of dose-dependent side effects; in large doses, it may cause generalized tonic-clonic seizures, altered consciousness and respiration, apnea during seizures, and a fatal outcome cannot be ruled out.
Treatment: administration of anticonvulsants, forced diuresis. If necessary - controlled ventilation.

Enhances the effects of psychostimulants, antidepressants.
Reduces the action of narcotic analgesics, hypnotics, neuroleptics, anxiolytics, anticonvulsants.
The effect of niketamide is reduced by aminosalicylic acid, opinozid, phenothiazine derivatives, and general anesthesia medications.
The pressor effect of niketamide is increased by monoamine oxidase inhibitors.
Niketamide contributes to the development of intolerance to fthivazide. The convulsive action of niketamide is enhanced by reserpine, aminazine.
Niketamide is ineffective in the context of deep anesthesia.

Has an analeptic effect. Stimulates the central nervous system: exerts an excitatory effect on the vasomotor center of the medulla oblongata (especially when this center is depressed), leading to an indirect increase in systemic arterial pressure. Excites the respiratory center due to its stimulating influence on the chemoreceptors of the carotid sinus reflexogenic zone, resulting in an increase in the frequency and depth of respiratory movements. The drug does not have a direct stimulating effect on the heart or a direct stimulating vasoconstrictive effect.

Well absorbed by any route of administration. Undergoes rapid biotransformation in the liver, resulting in the formation of inactive metabolites, which are primarily excreted by the kidneys.